Optimization of immunologic testing

Dried Blood Spot Assays: A Review

Many Canadian serosurveys have opted to use dried blood spot (DBS) tests as a practical means to study population-level SARS-CoV-2 seroprevalence. Tens of thousands of Canadians have received DBS kits in the mail. In this article, now published in PLOS ONE, researchers, including several CITF members, set out to determine which of the available [...]

2021-12-20T10:01:34-05:00December 20, 2021|Optimization of immunologic testing|

Designing serological assays with high diagnostic potential

In a not-yet peer-reviewed preprint, CITF-funded investigator Dr. Andrei Drabovich and colleagues from the University of Alberta, designed and evaluated the performance of serological diagnostics, used to measure the presence of SARS-CoV-2 antibodies. The particular assays studied, known as immunoprecipitation - parallel reaction monitoring (IP-PRM) and immunoprecipitation - selected reaction monitoring (IP-SRM), use a [...]

2021-11-02T10:25:42-04:00November 2, 2021|Optimization of immunologic testing|

A Canadian platform to study the antibody response to SARS-CoV-2 infection and vaccination

A group of Canadian researchers has developed a set of standardized, high-throughput serological assays to detect antibodies against SARS-CoV-2. Multiple studies estimating the seroprevalence of various populations in Canada – including over half of those funded by the CITF – use this platform, making it possible to harmonize and compare their results nationwide. In [...]

2021-11-02T11:30:55-04:00October 29, 2021|Optimization of immunologic testing|

‘Made-in-Canada’ assays perform well to measure seroprevalence

Despite the many assays available to test for SARS-CoV-2 antibodies, a gold standard has not yet been established. In an article now published in PLOS ONE, CITF Testing Working Group members Dr. Anne-Claude Gingras from the University of Toronto, and Dr. Steven Drews from Canadian Blood Services, evaluate multiple testing platforms and the concordance [...]

2021-10-05T10:23:19-04:00October 5, 2021|Optimization of immunologic testing|

A finger prick to test for SARS-CoV-2 antibodies

A team of Vancouver investigators, led by Dr. Agatha Jassem of the British Columbia Centre for Disease Control (BCCDC) and partially funded by the CITF, assessed SARS-CoV-2 serological testing using two methods: finger pricking (dried blood spot or DBS) and traditional venipuncture (blood draw with a needle). Their observations, in pre-print and therefore not [...]

2021-08-09T16:38:47-04:00August 10, 2021|Optimization of immunologic testing|

Vancouver researchers develop a quantitative SARS-CoV-2 viral load test

A group of researchers at Simon Fraser University, the BC Centre for Excellence in HIV/AIDS and Providence Health care led by CITF-funded researcher Dr. Zabrina Brumme have developed a method to quantify SARS-CoV-2 virus levels in human biological specimens using a technique called droplet digital RT-PCR (RT-ddPCR).   Key points: This method can be [...]

2021-06-08T13:29:49-04:00June 8, 2021|Optimization of immunologic testing|

‘Made-in-Canada’ assays perform well to measure seroprevalence

A recent preprint, not yet peer reviewed, by CITF Testing Working Group members Dr. Anne-Claude Gingras from University of Toronto, and Dr. Steven Drews from Canadian Blood Services, compared multiple assays and concluded ‘Made-in-Canada’ ones performed well.   Blood samples were collected through Canadian Blood Services between April and September 2020. A total of [...]

2021-09-30T11:36:46-04:00May 25, 2021|Optimization of immunologic testing|

Dried Blood Spot Assays: A Review

Many Canadian serosurveys have opted to use dried blood spot (DBS) tests as a practical means to study population-level SARS-CoV-2 prevalence. Tens of thousands of Canadians have received DBS kits in the mail. In this preprint, not yet peer-reviewed, researchers, including several CITF members, set out to determine which of the available DBS assays [...]

2021-04-13T10:49:06-04:00April 13, 2021|Optimization of immunologic testing|

A new testing strategy for the prompt detection of SARS-CoV-2 variants of concern

As the pandemic continues to evolve, it has become increasingly important to systematically adapt testing capacities to detect all variants of concern. In a recently published article, CITF-funded researcher Dr. Marc Romney and his team at the University of British Columbia proposed a new testing strategy that can rapidly detect circulating variants, and which [...]

2021-04-01T16:00:00-04:00March 23, 2021|Optimization of immunologic testing|

SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline

Researchers from Public Health Ontario and the University of Toronto found that there was a drop in the number of samples with detectable antibodies over time using the Abbott Architect SARS-CoV-2 IgG assay, but not when using the Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG test. The study provides evidence that there exists potentially significant variability in assays, which may give the impression of waning protection against COVID infection.

2021-03-29T18:06:41-04:00January 5, 2021|Optimization of immunologic testing|
Go to Top